![NCI will form an ad hoc committee to review screening trials The future of ECOG-ACRIN's slowly-accruing TMIST is in question](https://cdn.cancerletter.com/media/2020/09/24200818/TMIST_4x3.jpg)
![NCI will form an ad hoc committee to review screening trials The future of ECOG-ACRIN's slowly-accruing TMIST is in question](https://cdn.cancerletter.com/media/2020/09/24200818/TMIST_4x3.jpg)
Cover Story
NCI's cancer screening trials may be falling victim to the COVID-19 pandemic.
In Brief
Clinical Roundup
Drugs & Targets
![Drugs & Targets](https://cdn.cancerletter.com/media/2019/05/03161633/targets2.jpg)
![Drugs & Targets](https://cdn.cancerletter.com/media/2019/05/03161633/targets2.jpg)
Trending Stories
- Solving problems doctors can’t fix: How Georgetown’s medical-legal partnership saves lives by including lawyers on cancer care teams
Why every cancer center needs a Cancer LAW Project - Before the Olympics were smoke-free, tobacco brand deals ran rampant
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- ACS is using an AI-powered platform in the largest-ever population study of Black women
Time and resources freed up from data management will go to outreach and access - Georgetown-MedStar: Patients with cancer can rely on our lawyers to fight legal issues that harm health
- How a Georgetown med school student found her calling in surgery, law, and health equity